An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.
The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification.
Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program.
Sept. 24, 2024 -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of a third interim